Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 389

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts

Open access
Mehand, Massinissa Si, Al-Shorbaji, Farah, Millett, Piers, Murgue, Bernadette·2018·Antiviral Research

Abstract

&NA; The Research and Development (R&D) Blueprint is a World Health Organization initiative to reduce the time between the declaration of a public health emergency and the availability of effective diagnostic tests, vaccines, and treatments that can save lives and avert a public health crisis. The scope of the Blueprint extends to severe emerging diseases for which there are insufficient or no presently existing medical countermeasures or pipelines to produce them. In February 2018, WHO held an informal expert consultation to review and update the list of priority diseases, employing a prioritization methodology which uses the Delphi technique, questionnaires, multi‐criteria decision analysis, and expert review to identify relevant diseases. The committee determined that, given their potential to cause a public health emergency and the absence of efficacious drugs and/or vaccines, there is an urgent need for accelerated R&D for (in no order of priority) Crimean‐Congo haemorrhagic fever, Ebola virus and Marburg virus disease, Lassa fever, Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), Nipah and henipaviral diseases, Rift Valley fever and Zika virus disease. The experts also included “Disease X,” representing the awareness that a previously unknown pathogen could cause a major public health emergency. This report describes the methods and results of the 2018 prioritization review. HighlightsEmerging infectious diseases pose an important threat for humans.Many of these diseases do not have medical countermeasures.WHO and partners are tackling this issue to advance product R&D for a set of emerging priority diseases.A methodology has been developed and externally reviewed in 2016 to identify a priority list of diseases in need of R&D.This methodology was applied in 2017 and 2018 to review the WHO R&D Blueprint priority list of diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.antiviral.2018.09.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 389

Metadata

Authors
Mehand, M. S., Al-Shorbaji, F., Millett, P., & Murgue, B.
Venue
Antiviral Research
Publisher
Elsevier BV
Published
2018-11
Volume
159
Pages
63-67
ISSN
0166-3542 (ISSN-L)
OpenAlex
W2893827872
Cited by
389
References
3
FWCI
23.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. https://app.cochat.ai/papers/10.1016/j.antiviral.2018.09.009
The paper
Mehand, M. S., Al-Shorbaji, F., Millett, P., & Murgue, B. (2018). The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antiviral Research. https://doi.org/10.1016/j.antiviral.2018.09.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.